Carcinoid syndrome classification: Difference between revisions
Jump to navigation
Jump to search
| Line 5: | Line 5: | ||
==Classification== | ==Classification== | ||
* | *Gastroenteropancreatic neuroendocrine tumors are classified based upon their origin from the embryonic divisions of the alimentary tract: | ||
#Foregut (bronchial, stomach) | |||
#Midgut (small intestine, appendix, cecum) | |||
#Hindgut (distal colon, rectum, genitourinary) | |||
*GET-NETs produce a number of secretory products, resulting in a wide range of clinical symptoms.<ref name="pmid29260133">{{cite journal |vauthors=Büyükaşık K, Arı A, Tatar C, Akçe B, Sevinç MM, Sarı S, Paşaoğlu E, Bektaş H |title=Clinicopathological features of gastroenteropancreatic neuroendocrine tumors: A retrospective evaluation of 42 cases |journal=Turk J Surg |volume=33 |issue=4 |pages=279–283 |date=2017 |pmid=29260133 |doi=10.5152/UCD.2017.3685 |url=}}</ref> <ref name="pmid26911175">{{cite journal |vauthors=Davies L, Weickert MO |title=Gastroenteropancreatic neuroendocrine tumours: an overview |journal=Br J Nurs |volume=25 |issue=4 |pages=S12–5 |date=2016 |pmid=26911175 |doi=10.12968/bjon.2016.25.4.S12 |url=}}</ref><ref name="pmid21311954">{{cite journal |vauthors=Oberg K, Castellano D |title=Current knowledge on diagnosis and staging of neuroendocrine tumors |journal=Cancer Metastasis Rev. |volume=30 Suppl 1 |issue= |pages=3–7 |date=March 2011 |pmid=21311954 |doi=10.1007/s10555-011-9292-1 |url=}}</ref> | *GET-NETs produce a number of secretory products, resulting in a wide range of clinical symptoms.<ref name="pmid29260133">{{cite journal |vauthors=Büyükaşık K, Arı A, Tatar C, Akçe B, Sevinç MM, Sarı S, Paşaoğlu E, Bektaş H |title=Clinicopathological features of gastroenteropancreatic neuroendocrine tumors: A retrospective evaluation of 42 cases |journal=Turk J Surg |volume=33 |issue=4 |pages=279–283 |date=2017 |pmid=29260133 |doi=10.5152/UCD.2017.3685 |url=}}</ref> <ref name="pmid26911175">{{cite journal |vauthors=Davies L, Weickert MO |title=Gastroenteropancreatic neuroendocrine tumours: an overview |journal=Br J Nurs |volume=25 |issue=4 |pages=S12–5 |date=2016 |pmid=26911175 |doi=10.12968/bjon.2016.25.4.S12 |url=}}</ref><ref name="pmid21311954">{{cite journal |vauthors=Oberg K, Castellano D |title=Current knowledge on diagnosis and staging of neuroendocrine tumors |journal=Cancer Metastasis Rev. |volume=30 Suppl 1 |issue= |pages=3–7 |date=March 2011 |pmid=21311954 |doi=10.1007/s10555-011-9292-1 |url=}}</ref> | ||
Revision as of 18:55, 7 January 2019
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Anum Gull M.B.B.S.[2]Parminder Dhingra, M.D. [3]
Overview
Classification
- Gastroenteropancreatic neuroendocrine tumors are classified based upon their origin from the embryonic divisions of the alimentary tract:
- Foregut (bronchial, stomach)
- Midgut (small intestine, appendix, cecum)
- Hindgut (distal colon, rectum, genitourinary)
- GET-NETs produce a number of secretory products, resulting in a wide range of clinical symptoms.[1] [2][3]
|
Carcinoid syndrome Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Carcinoid syndrome classification On the Web |
|
American Roentgen Ray Society Images of Carcinoid syndrome classification |
|
Risk calculators and risk factors for Carcinoid syndrome classification |
| Foregut | Midgut | Hindgut | |
|---|---|---|---|
| Location |
|
|
|
| Hormones produced |
|
|
Variable |
| Possibility of carcinoid syndrome | Rare, and atypical when it happens | Classic | Rare |
References
- ↑ Büyükaşık K, Arı A, Tatar C, Akçe B, Sevinç MM, Sarı S, Paşaoğlu E, Bektaş H (2017). "Clinicopathological features of gastroenteropancreatic neuroendocrine tumors: A retrospective evaluation of 42 cases". Turk J Surg. 33 (4): 279–283. doi:10.5152/UCD.2017.3685. PMID 29260133.
- ↑ Davies L, Weickert MO (2016). "Gastroenteropancreatic neuroendocrine tumours: an overview". Br J Nurs. 25 (4): S12–5. doi:10.12968/bjon.2016.25.4.S12. PMID 26911175.
- ↑ Oberg K, Castellano D (March 2011). "Current knowledge on diagnosis and staging of neuroendocrine tumors". Cancer Metastasis Rev. 30 Suppl 1: 3–7. doi:10.1007/s10555-011-9292-1. PMID 21311954.